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11 Abstract The PI3K pathway is a key mechanism of
12 trastuzumab resistance, but early attempts to indirectly target
13 this pathway with mTOR inhibitors have had limited suc-
14 cess. We present the results of a preclinical study of the
15 selective alpha/delta isoform dominant PI3K inhibitor BAY
16 80-6946 tested alone and in combination with HER2-tar-
17 geted therapies in HER2-positive cell lines, including mod-
18 els with acquired resistance to trastuzumab and/or lapatinib.
19 A panel of HER2-positive breast cancer cells were proﬁled
20 for their mutational status using Sequenom MassARRAY,
21 PTEN status byWestern blot, and anti-proliferative response
22 to BAY 80-6946 alone and in combination with the HER2-
23 targeted therapies trastuzumab, lapatinib and afatinib.
24 Reverse phase protein array was used to determine the effect
25 of BAY 80-6946 on expression and phosphorylation of 68
26 proteins including members of the PI3K and MAPK path-
27 ways. The Boyden chamber method was used to determine if
28 BAY80-6946 affected cellular invasion andmigration. BAY
29 80-6946 has anti-proliferative and anti-invasive effects when
30 used alone in our panel of cell lines (IC50’s 3.9–29.4 nM).
31BAY 80-6946 inhibited PI3K signalling and was effective in
32cells regardless of their PI3K, P53 or PTEN status. The
33combination of HER2-targeted therapies and BAY 80-6946
34inhibited growth more effectively than either therapy used
35alone (with clear synergism in many cases), and can restore
36sensitivity to trastuzumab and lapatinib in cells with acquired
37resistance to either trastuzumab and/or lapatinib. The addi-
38tion of BAY 80-6946 to HER2-targeted therapy could rep-
39resent an improved treatment strategy for patients with
40refractory metastatic HER2-positive breast cancer, and
41should be considered for clinical trial evaluation. 2
43Keywords PI3K inhibitor  HER2-positive breast
44cancer  Acquired resistance to HER2-targeted therapies 
45Sequenom MassArray  Reverse phase protein array
46Introduction
47HER2-positive breast cancer accounts for 15–20 % of all
48breast cancers and is associated with shorter time to pro-
49gression and decreased overall survival [1]. Trastuzumab, a
50monoclonal antibody targeted to HER2, has signiﬁcantly
51improved outcomes in both the adjuvant and metastatic
52settings [2], but resistance to trastuzumab remains a problem.
53Lapatinib, a small molecule tyrosine kinase inhibitor (TKI)
54against HER2 and EGFR, currently in use as a second-line
55therapy in patients who have progressed on trastuzumab
56therapy [3], is effective in some patients who acquire resis-
57tance to trastuzumab. However, the efﬁcacy of lapatinib is
58also limited by the development of acquired resistance.
59The phosphatidylinositol-3-kinase (PI3K) pathway, a
60major signalling mediator in cancer [4] is activated down-
61stream of HER2, and this pathway has been strongly impli-
62cated as amediator of trastuzumab resistance in breast cancer
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63 [5, 6] and has recently been associated with lapatinib resis-
64 tance [7, 8]. Preclinical data suggest that targeting a PI3K
65 signalling node called mammalian target of rapamycin
66 (mTOR), in combination with HER2-inhibition could over-
67 come HER2-positive breast cancer resistance to HER2-tar-
68 geted therapy [4], However, the clinical efﬁcacy of mTOR
69 inhibitors in HER2-positive breast cancer has been disap-
70 pointing [9], likely in part due to inhibition of mTOR acti-
71 vating a feedback loop which up regulates PI3K activity,
72 thereby attenuating the anti-tumour efﬁcacy of mTOR
73 inhibitors [10].
74 We believe that directly targeting PI3K can overcome
75 the limitation of feedback activation mediated by mTOR
76 inhibition. BAY 80-6946 a novel, potent, highly selective
77 PI3K inhibitor [11–14], able to induce apoptosis in vitro
78 [11], was well tolerated in a Phase I clinical trial [15]. In
79 the study presented here, we show that the novel PI3K
80 inhibitor, BAY 80-6946, potently inhibited the growth of
81 ﬁve HER2-positive cell lines and ﬁve HER2-positive lines
82 with acquired trastuzumab/lapatinib resistance. We found
83 that the combination of BAY 80-6946 and HER2-targeted
84 therapies more effectively inhibited cell growth than either
85 therapy used alone, with clear synergism in many cases,
86 and that the addition of the PI3K inhibitor could restore
87 sensitivity to HER2-targeted therapies in cells with
88 acquired resistance to trastuzumab and lapatinib.
89 Materials and methods
90 Cell culture
91 Human HER2-positive breast cancer cell lines were obtained
92 from the National Institute for Cellular Biotechnology
93 (NICB), Dublin City University, and the Division of Hae-
94 matology/Oncology, University of California, Los Angeles
95 (UCLA). Resistant variants were developed by continuous
96 growth in the relevant drug (SKBR3-T (NICB): 10 lg/ml
97 trastuzumab; SKBR3-L (NICB): 250 nM lapatinib; SKBR3-
98 TL (NICB): 5 lg trastuzumab and 150 nM lapatinib;
99 HCC1954-L (NICB): 1,250 nM lapatinib; BT474-Res
100 (UCLA): 100 ug/ml trastuzumab) for 6 months, with drug
101 refreshed twice weekly. All cell lines were grown in RPMI-
102 1640 media (Sigma) supplemented with 10 % FCS and 1 %
103 Penicillin/Streptomycin (P/S) and maintained at 37 C with
104 5 % CO2. Cell line identity was conﬁrmed by DNA ﬁnger-
105 printing,whichwas performed by SourceBiosciences
TM. Cell
106 lines were Mycoplasma tested before and after the in vitro
107 experiments. Trastuzumab (21 mg/ml) was obtained from St
108 James University Hospital and prepared in bacteriostatic
109 water. Lapatinib (10.8 mM) and Afatinib (20.6 mM) were
110 purchased from Sequoia Chemicals and stock solutions pre-
111 pared in dimethylsulfoxide (DMSO). BAY 80-6946 (10 mM)
112was obtained under MTA from Bayer Pharmaceuticals and
113prepared in DMSO and 5 % triﬂuoroacetic acid (TFA).
114Proliferation assays
115For all resistant cell lines, drug was removed from the cells
116at least 7-days prior to starting assays, and no P/S was
117added to media during proliferation assays. 3 9 10
4 cells/
118well were seeded in 96-well plates, apart from BT474 and
119BT474-Res which were seeded at 5 9 10
4 cells/well.
120Plates are incubated overnight at 37 C to allow cells to
121adhere. Drugs were added to the plates at speciﬁc con-
122centrations and incubated at 37 C. Following 5-day
123incubation, during which control cells attained 80–90 %
124conﬂuence, all media were removed from the plates, and
125washed once with PBS. Proliferation was measured using
126the acid phosphatase assay as previously described [16].
127Invasion and migration assays
128Invasion and migration assays were performed using the
129Boyden chamber method as previously described [16].
130After 24 h, the plates were removed from the incubator.
131Matrigel and media were removed, the insert stained with
132crystal violet for 10 min, then rinsed three times in distilled
133water and left to dry at room temperature. Cells were
134counted at 2009 magniﬁcation in 10 views from each well,
135with the average result taken to represent the number of
136invading/migrating cells in that well.
137Protein extraction from cell lines
1384.5 9 10
5 cells were seeded into 6-well plates and left to
139adhere overnight. Cells were treated with 1 nM BAY-
140806946 or an equivalent concentration of DMSO-TFA
141(vehicle control). Protein was extracted 6 and 24 h post
142treatment as indicated in Supplementary Materials and
143methods and stored at -80 C.
144Reverse phase protein array analysis
145RPPA was carried out as previously described by us [5,
14617]. The antibodies used are listed in Supplementary
147materials and methods. RPPA analysis was carried out
148using triplicate biological replicates.
149DNA extraction and Sequenom MassArray analysis
150DNA extraction was performed using an AllPrep
TM DNA/
151RNA mini Kit (Qiagen) as per manufacturer’s instructions.
152Mass spectrometry-based genotyping (Sequenom Mass-
153ARRAY, Sequenom, San Diego, CA) was applied to detect
154a total of 547 single nucleotide mutations in 49 cancer-
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155 related genes, which are listed in Supplementary materials
156 and methods. Reactions where[15 % of the resultant mass
157 ran in the mutant site were scored as positive.
158 Statistical analysis
159 IC50 and combination index (CI) values @ effective dose 50
160 (ED50) were calculated using CalcuSyn software (BioSoft).
161 A CI value of\0.9 is considered synergistic, 0.9–1.1 is con-
162 sidered additive and [1.1 is considered antagonistic. The
163 Student’s t test was used to compare the effect of BAY
164 80-6946 on invasion and migration, and the effect of BAY
165 80-6946, lapatinib and the combination of both drug on pro-
166 tein expression and phosphorylation in our RPPA data.
167 A Kruskal–Wallis non-parametric test was performed to
168 compare trastuzumab alone, BAY 80-6946 alone and the
169 combination. p\0.05was considered statistically signiﬁcant.
170 Results
171 HER2-positive breast cancer cell lines respond to BAY
172 80-6946 regardless of their mutational status
173 and response to lapatinib, afatinib or trastuzumab
174 A panel of HER2-positive cell lines including matched
175 models of acquired trastuzumab, lapatinib and combined
176trastuzumab and lapatinib resistance, were analysed by
177Sequenom MassArray for somatic mutations in 53 dif-
178ferent genes (Table 1). Mutations in the PIK3CA gene
179were identiﬁed in BT474 (K111N), HCC1954 (H1047R)
180and MDAMB453 (H1047R) cells. The mutational status
181of PI3K, TP53 or the expression of PTEN did not
182change between parental cell lines and models of
183acquired resistance to trastuzumab and/or lapatinib
184(Table 1).
185BAY 80-6946 achieves an IC50 in the panel of cell lines
186ranging from 3.9 ± 0.8 nM in BT474 to 29.4 ± 4.7 nM in
187MDAMB453 cells, and is effective in cell lines regardless
188of their PI3K or P53 mutational status (Table 1). Models of
189acquired resistance to trastuzumab have a higher IC50 to
190BAY 80-6946 than their matched parental cell lines
191(SKBR3 = 7.2 ± 0.8 nM; SKBR3-T = 26.2 ± 6.2 nM:
192BT474 = 3.9 ± 0.8 nM; BT474-Res = 6.25 ± 0.8 nM).
193Treatment with BAY 80-6946 (at a non-lethal dose) for
19424 h signiﬁcantly decreased invasion in both cell lines
195(BT474 p = 0.008; MDAMB453 p = 0.008) but had no
196effect on migration (Supplementary Fig. 1).
197We studied the effect of lapatinib and afatinib (dual
198EGFR/HER2 inhibitors) in our panel of cell lines. Lapati-
199nib IC50s range from 33.3 ± 9.5 nM in BT474 cells up to
200greater than 500 nM in cells with acquired lapatinib
201resistance. The cell lines with acquired lapatinib resistance
202SKBR3-L, -TL and HCC1954-L did not achieve an IC50 at
Table 1 Comparative mutational analysis as determined by Seque-
nom MassArray of mutations in PIK3CA and TP53; PTEN status as
assessed by Western blotting; PI3K Signalling as deﬁned by
expression and activation of PI3K signalling factors; IC50 values
assessing for BAY 80-6946, lapatinib and afatinib, and the effect of
trastuzumab on growth inhibition in a panel of HER2-positive cell
lines including matched models of acquired trastuzumab (-T and -
Res), lapatinib (-L) and –TL resistance
Cell line Acquired
resistance
Mutational status PI3K signalling factors Response to targeted therapies (IC50)
Name PIK3CA TP53 PTEN PI3K
Signalling
BAY
80-6946
(nM)
Lapatinib (nM) Afatinib
(nM)
Trastuzumab %
growth inhibition
at 10 lg/ml
SKBR3 N/A Wt Wt Low Active 7.2 ± 0.8 65.1 ± 11.8 6.2 ± 1.7 39.8 ± 5.2
SKBR3-L L Wt Wt Low Active 7.6 ± 4.0 \50 % inhibition
@ 500 nM
32.1 ± 6.1 15.9 ± 8.2
SKBR3-T T Wt Wt Low Active 26.2 ± 6.2 51.2 ± 2.8 3.8 ± 2.4 12.5 ± 4.7
SKBR3-TL T ? L Wt Wt Low Active 8.0 ± 1.4 \50 % inhibition
@ 500 nM
38.5 ± 1.1 11.2 ± 6.1
BT474 N/A K111N Wt High Active 3.9 ± 0.8 33.3 ± 9.5 6.3 ± 1.9 43.6 ± 4.1
BT474-Res T K111N Wt High Active 6.25 ± 0.8 108.7 0.8 i 4.6 ± 1.5 -1.2 ± 2.7
HCC1954 N/A H1047R Wt Low Active 4.9 ± 1.0 291.4 ± 42.2 44.2 ± 9.7 -10.0 ± 19.0
HCC1954-L L H1047R Wt Low Active 9.2 ± 2.3 \50 % inhibition
@ 500 nM
54.0 ± 12.2 -2.0 ± 14.0
HCC1569 N/A H1047R Wt High Active 29.4 ± 4.7 291.4 4.70i 19.8 ± 7.4 7.9 ± 8.1
MDAMB453 N/A H1047R Wt Low Active 3.9 ± 1.9 [2,000 [1,000 -1.5 ± 2.1
Standard deviations are representative of triplicate independent experiments
N/A parental cell lines that do not have acquired resistance, wt wild-type
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203 greater than 500 nM lapatinib whilst MDAMB453 cells
204 did not achieve an IC50 at greater than 2 lM lapatinib.
205 Afatinib IC50s range from 3.8 ± 2.4 nM in SKBR3-T cells
206 to greater than 1 lM in MDAMB453 cells. Interestingly,
207 the SKBR3-L and SKBR3-TL cells have a greater IC50 to
208 afatinib than that seen in SKBR3 cells; however the same
209 affect is not observed in the HCC1954-L cell line relative
210 to HCC1954 cells. Cells have varying sensitivity to trast-
211 uzumab when used alone, achieving between
212 43.6 ± 4.1 % growth inhibition in BT474 cells to no
213 growth inhibition (e.g. in HCC1954 cells).
214 The effect of BAY 80-6946 on cell signalling in a panel
215 of HER2-positive cell lines
216 The expression of PI3K-P110-alpha was not signiﬁcantly
217 affected by BAY 80-6946 treatment in any cell line tested
218 including those models of acquired resistance to either
219 trastuzumab and/or lapatinib. AKT phosphorylation (S473)
220 was signiﬁcantly reduced in 3/5 cell lines tested (SKBR3,
221 BT474 and MDAMB453); however it remained unchanged
222 in HCC1569 and increased in HCC1954 cells (Table 2,
223 Supplementary Fig. 2). In SKBR3 and BT474 cells which
224 had diminished AKT activation (S473) in response to BAY
225 80-6946 treatment, a corresponding decrease in phos-
226 phorylation of mTOR (S2481) was observed. In the models
227 of acquired resistance, AKT phosphorylation (S473) was
228 reduced in SKBR3-L, -T, -TL but not in HCC1954-L and
229 BT474-RES cells whose AKT phosphorylation remains
230 unchanged.
231 We found in all models tested that treating cells with
232 1 nM BAY 80-6946 did not result in increases in PARP
233 cleavage or in cleavage of caspase-7, -8 or -9 (results not
234 shown), indicating that BAY 80-6946 does not induce
235 apoptosis in our cells at the concentration tested.
236 We found that HER2 (Y1248) was signiﬁcantly
237 increased in HCC1954 cells (p = 0.003) and was increased
238 in BT474 cells treated for 6 with BAY 80-6946 (p = 0.06).
239 HER3 expression or activation (Y1289) was not altered
240 after BAY 80-6946 treatment in parental HER-2 positive
241 cells. We also saw a signiﬁcant increase in MAPK acti-
242 vation (T202/Y204) in HCC1954 (p = 0.006), BT474
243 (p = 0.03) and MDAMB453 (p = 0.04) cells after treat-
244 ment with BAY 80-6946.
245 Interestingly in models of acquired lapatinib resistance,
246 treatment with BAY 80-6946 signiﬁcantly reduced HER3
247 phosphorylation (Y1289) (SKBR3-L (p = 0.03) and
248 HCC1954-L (p = 0.03)), whilst a similar effect was seen
249 in BT474-RES cells (p = 0.04) but not in the SKBR3-TL
250 cells or SKBR3-T cells. MAPK activation (T202/Y204)
251 was also signiﬁcantly increased in SKBR3-T (p = 0.05)
252 cells after treatment with BAY 80-6946. T
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253 Combinations of lapatinib and BAY 80-6946 are
254 synergistic in HER2-positive breast cancer cell lines
255 including those with acquired lapatinib resistance
256 Combinations of lapatinib and BAY 80-6946 enhance
257 growth inhibition relative to testing either drug alone in all
258 cell lines tested (Fig. 1). Lapatinib has a synergistic
259 response in the majority of HER2-positive breast cancer
260 cell lines when tested in combination with BAY 80-6946.
261 (BT474-RES CI @ ED50 = 0.32 ± 0.12 ranging to
262 SKBR3-L CI @ ED50 = 0.85 ± 0.23) (Table 4). Despite
263 lapatinib resistant models SKBR3-L, HCC1954-L and
264 SKBR3-TL having limited sensitivity to lapatinib, the
265 combination of lapatinib and BAY 80-6946 is still syner-
266 gistic with clear restoration of sensitivity to lapatinib in
267 these cell lines. This trend is also observed in the
268trastuzumab resistant cell lines BT474-Res and SKBR3-T,
269whereby the combination of lapatinib plus BAY 80-6946
270remains highly synergistic (Table 3).
271MAPK signalling activation by BAY 80-6946 is
272inhibited by co-treatment with BAY 80-6946
273and lapatinib
274After 6 h treatment with BAY 80-6946, MAPK (T202/
275Y204) phosphorylation was signiﬁcantly increased in three
276of the ﬁve parental cell lines. We, therefore, performed a
27730 min RPPA experiment in the SKBR3 and HCC1954
278models and in the matched models of acquired lapatinib
279resistance to analyse the effect of lapatinib and BAY
28080-6946 alone and in combination on MAPK and MEK
281signalling (Table 4, Supplementary Fig. 3).
Fig. 1 Efﬁcacy of lapatinib (diamond), BAY 80-6946 (square) and a
combination of lapatinib and BAY 80-6946 (triangle) in a panel of
HER2-positive cell lines, including those with acquired resistance to
either trastuzumab (-T or -Res), lapatinib (-L) or the combination of
trastuzumab and lapatinib (-TL). Error bars are representative of
standard deviations across triplicate experiments. The ratio of
lapatinib: BAY 80-6946 in this assay is ﬁxed at 5:1
AQ1
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282 Treatment with BAY 80-6946 for 30 min increased
283 MAPK (T202/Y204) and MEK (S217/221) phosphoryla-
284 tion in SKBR3 and SKBR3-L cells, whilst there was an
285 increase in MAPK (T202/Y204) signalling in HCC1954
286 and HCC1954-L cells. BAY 80-6946 alone decreased
287 MEK (S217/221) phosphorylation in HCC1954 cells.
288 Treatment with lapatinib reduced MAPK (T202/Y204)
289 phosphorylation relative to treatment with BAY 80-6946 in
290 all cell lines tested; however it only reduced MEK (S217/
291 221) phosphorylation in the SKBR3-L and HCC1954-L
292 cell lines. Finally, treatment with the combination of BAY
293 80-6946 and lapatinib inhibited the increase in MAPK
294 (T202/Y204) phosphorylation by BAY 80-6946 but did not
295 reduce further the phosphorylation of either MAPK (T202/
296 Y204) or MEK (S217/221) relative to treatment with la-
297 patinib alone in all cell lines tested.
298 Combinations of afatinib and BAY 80-6946 are
299 synergistic in HER2-positive cell lines
300 The combination of afatinib and BAY 80-6946 enhances
301 growth inhibition relative to testing either drug alone (Fig. 2).
302 Afatinib and BAY 80-6946 have an additive response in
303 SKBR3 cells (CI @ ED50 = 0.91 ± 0.13) and a synergistic
304 response in the remaining cell lines, (SKBR3-TLCI@ED50 =
305 0.48 ± 0.02 toHCC1569CI@ED50 = 0.58 ± 0.13) (Fig. 2,
306 Table 3). Indeed, the combination is far more synergistic in
307 BT474-Res, SKBR3-T, SKBR3-L and SKBR3-TL than in
308 BT474 and SKBR3 parental cells, respectively. Interestingly,
309 afatinib/BAY 80-6946 synergism is thus enhanced in cell line
310 models of acquired resistance to trastuzumab and/or lapatinib.
311Combinations of trastuzumab and BAY 80-6946
312improve response to either drug tested alone in HER2-
313positive breast cancer cells including those
314with acquired trastuzumab resistance
315The combination of trastuzumab and BAY 80-6946 resul-
316ted in signiﬁcantly improved growth inhibition compared
317to either therapy alone in three of the four parental cell
318lines tested (BT474, HCC1954 and SKBR3) (Fig. 3).
319Combinations of BAY 80-6946 and trastuzumab signiﬁ-
320cantly enhanced growth inhibition in models of acquired
321trastuzumab and/or lapatinib resistance (BT474-Res,
322SKBR3-L, -T, -TL (p\ 0.05)) but not in HCC1954-L
323cells.
324PI3K inhibition does not sensitise de novo resistant
325HER2-positive breast cancer cell lines to HER2
326inhibitors
327Although our data shows the beneﬁt of combining BAY
32880-6946 with HER2-targeted therapies in cells which are
329either sensitive to or have acquired resistance to HER2-
330inhibitors, combinations of BAY 80-6946 and lapatinib or
331afatinib do not demonstrate an increase in proliferation
332inhibition in MDAMB453 cells which have de novo la-
333patinib resistance (Supplementary Fig. 4). However,
334despite their resistance to HER2 inhibitors, these cells are
335still sensitive to BAY 80-6946 (Table 1) and no increased
336proliferation is observed when tested with the combination
337of lapatinib and BAY 80-6946.
Table 3 Combination Index values at effective dose 50 for lapatinib and afatinib in a panel of HER2-positive cell lines including models of
acquired trastuzumab and/or lapatinib resistance
Cell line Lap:80-6846 Afat:80-6946 IC50 (nM) IC50 (nM) IC50 (nM) IC50 (nM)
ED50 ED50 Lapatinib Lapatinib in
combination
with BAY
80-6946
Afatinib Afatinib in
combination
with BAY
80-6946
SKBR3 0.68 ± 0.08 0.91 ± 0.13 65.1 ± 11.8 17.8 ± 8.1 6.2 ± 1.7 2.7 ± 0.3
SKBR3-L 0.85 ± 0.23 0.50 ± 0.09 \50 % inhibition @ 500 nM 68.5 ± 11.0 32.1 ± 6.1 7.8 ± 4.5
SKBR3-T 0.44 ± 0.19 0.59 ± 0.18 51.2 ± 2.8 24.1 ± 6.9 3.8 ± 2.4 3.0 ± 0.8
SKBR3-TL 0.59 ± 0.09 0.48 ± 0.02 \50 % inhibition @ 500 nM 55.1 ± 6.0 38.5 ± 1.1 9.1 ± 1.5
BT474 0.48 ± 0.08 0.50 ± 0.05 33.3 ± 9.5 9.6 ± 4.3 6.3 ± 1.9 2.5 ± 0.1
BT474-Res 0.32 ± 0.20 0.52 ± 0.13 108.7 ± 10.5 5.4 ± 7.3 4.6 ± 1.5 4.0 ± 1.0
HCC1954 0.63 ± 0.10 0.73 ± 0.02 291.4 ± 42.2 17.8 ± 6.0 44.2 ± 9.7 1.4 ± 0.5
HCC1954-L 0.83 ± 0.07 0.46 ± 0.22 \50 % inhibition @ 500 nM 40.6 ± 7.5 54.0 ± 12.2 1.8 ± 0.7
HCC1569 0.80 ± 0.11 0.58 ± 0.13 291.4 ± 60.0 65.2 ± 3.8 19.8 ± 7.4 6.8 ± 0.5
IC50 values for testing lapatinib or afatinib alone and in combination with BAY 80-6946 to demonstrate the ability of BAY80-6946 to restore
sensitivity to the HER2-targeted inhibitor
Standard deviations are calculated from of triplicate independent experiments
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338Discussion
339Resistance to trastuzumab remains a signiﬁcant clinical
340problem, with up to 30 % of patients not responding to it in
341the metastatic setting [2]. Strong evidence has implicated
342the PI3K pathway in trastuzumab and lapatinib resistance
343[5, 6, 18], although data supporting the involvement of
344PI3K signalling in lapatinib resistance are somewhat con-
345ﬂicting [8, 19]. Preclinical testing of mTOR inhibitors led
346to anticipation that resistance to HER2 targeted therapies
347could be overcome, but their clinical beneﬁt has been
348somewhat disappointing [9], reﬂected in the results of the
349Phase 3 BOLERO-3 clinical trial [20]. We, therefore,
350hypothesised that targeting PI3K directly would represent a
351more optimal strategy, and that combined PI3K- and
352HER2-inhibition may represent an improved treatment
353strategy for HER2-positive breast cancer.
354BAY 80-6946 a novel, potent PI3K inhibitor with
355in vitro and in vivo efﬁcacy [11–14] was well tolerated in a
356phase I clinical trial [15] and we found it to have anti-
357proliferative effects in HER2-positive breast cancer cell
358lines regardless of their PI3K mutational status. We also
359found that BAY 80-6946 inhibited invasion but had no
360effect on migration. The PI3K pathway, like HER2 has
361previously been shown to up regulate invasion [21, 22], a
362crucial step in metastasis [23]. Therefore, it is encouraging
363to note that in addition to inhibiting proliferation, BAY
36480-6946 also inhibited invasion in HER2-positive cell
365lines. This may also suggest a potential role for BAY
36680-6946 in the adjuvant treatment of breast cancer as well
367as in the metastatic setting.
368In our cell line panel, we tested BAY 80-6946 at 1 nM
369to observe pure signalling effects, without the associated
370signalling interference associated with cell death. BAY
37180-6946 did not effectively inhibit AKT phosphorylation in
372all our cell lines at the concentration tested. However,
373previous reports have indicated that AKT phosphorylation
374is effectively inhibited in other models of cancer at higher
375concentrations (200 lmol/L) [13]. We believe that the
376reduction of PI3K signalling observed in some, but not all
377cell lines may thus in part reﬂect the dose of BAY 80-6946
378used in our RPPA signalling experiment (1 nM). In addi-
379tion, we have previously observed that pharmacokinetics
380including cellular uptake of kinase inhibitor drugs vary
381across cell lines [24] and also that PI3K promotes onco-
382genic activity through both AKT-dependent and AKT-
383independent mechanisms [25]. However, an elucidation of
384the exact reason(s) for the reduction of PI3K signalling in
385some but not all cell lines by BAY 80-6946 is beyond the
386scope of our article.
387In what is arguably the most important observation of
388this study, we found that combining BAY 80-6946 with the
389HER2-targeted therapies trastuzumab, lapatinib andT
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390 afatinib resulted in signiﬁcantly greater proliferation inhi-
391 bition relative to testing either drug alone in our panel of
392 cells including those with acquired resistance to trast-
393 uzumab and/or lapatinib. To evaluate BAY 80-6946’s
394 potential to restore the efﬁcacy of the HER-targeted ther-
395 apies in cells with acquired resistance; we compared the
396 IC50’s of lapatinib and afatinib used in combination with
397 BAY 80-6946 against the IC50 of lapatinib and afatinib
398 alone. In all cases, the IC50 of the HER-targeted therapy
399 was less in combination with BAY 80-6946 than as a single
400 agent. In SKBR3-L and HCC1954-L cells, lapatinib when
401 used with BAY 80-6946 achieved an IC50 that was similar
402 or less than the IC50 of lapatinib used alone in the corre-
403 sponding parental cell line, indicating that the addition of
404 BAY 80-6946 does restore sensitivity to lapatinib. Impor-
405 tantly, combinations of BAY 80-6946 with lapatinib and
406 afatinib were synergistic in all cell lines with acquired
407 resistance to lapatinib and/or trastuzumab, indicating a
408potential clinical beneﬁt to using combinations of the PI3K
409inhibitor BAY 80-6946 with HER-targeted agents in
410patients whose cancers have developed resistance to these
411HER2-targeted agents.
412Although PI3K inhibition has previously been shown by
413some to activate HER3 [26], possibly attenuating the anti-
414tumor effect of some PI3K inhibitors [27], we found that
415BAY 80-6946 did not activate HER3 phosphorylation in any
416cell line tested. We did, however, ﬁnd that when used alone,
417BAY 80-6946 activated HER2 phosphorylation. PI3K inhi-
418bition has also previously been shown to enhance HER sig-
419nalling resulting in compensatory MAPK signalling in
420HER2-positive breast cancer [28]. Because we observed
421increases inMAPK signalling, in some cases associated with
422increases in HER2 phosphorylation, after treatment with
423BAY 80-6946, we hypothesised that combining BAY
42480-6946 with lapatinib would overcome this MAPK acti-
425vation. We found that combining BAY 80-6946 with
Fig. 2 Efﬁcacy of afatinib (diamond), BAY 80-6946 (square) and a
combination of afatinib and BAY 80-6946 (triangle) in a panel of
HER2-positive cell lines, including those with acquired resistance to
either trastuzumab (-T or -Res), lapatinib (-L) or the combination of
trastuzumab and lapatinib (-TL). Error bars are representative of
standard deviations across triplicate experiments. The ratio of
lapatinib: BAY 80-6946 in this assay is ﬁxed at 1:1
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426 lapatinib inhibited MAPK (T202/Y204) phosphorylation by
427 BAY 80-6946 and instead resulted in a reduction of MAPK
428 signalling in all cell lines tested (with a parallel reduction in
429 MEK signalling in some models of acquired lapatinib
430 resistance). This ﬁnding may underlie, at least in part, the
431 synergy between BAY 80-6946 and HER2 inhibitors, and
432 further supports the argument that PI3K inhibition should be
433 used in combination with HER2-inhibitors.
434 In summary, BAY 80-6946 is effective as monotherapy in
435 HER2-positive breast cancer cells including models of
436 acquired resistance to trastuzumab and/or lapatinib. Combi-
437 nations of BAY 80-6946 with HER2-targeted therapies offer
438 greater beneﬁt than testing drugs alone and can restore sen-
439 sitivity to HER2-inhibitors in cells with acquired resistance to
440 trastuzumab and lapatinib. BAY 80-6946 also inhibits the
441 invasion of HER2-positive breast cancer cells. Taken toge-
442 ther, our data argue that the addition of the PI3K inhibitor
443 BAY80-6946 toHER2-targeted therapy shouldbe considered
444 for clinical trial evaluation in patients with HER2-positive
445 breast cancer whose disease has become refractory to HER2-
446 targeted therapies such as trastuzumab or lapatinib.
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